loading page

Thalidomide combined with interleukin-2 and interferon α-2b in the treatment of refractory multicentric Castleman disease:Two cases report and literature review
  • +6
  • Zhendong He,
  • Shengsheng Zhou,
  • Haiyan Yang,
  • Fengxiang Huang,
  • Qinli Mo,
  • Yehong Bin,
  • Dong Lan,
  • Jie Ma,
  • Zhigang Peng
Zhendong He
Guangxi Medical University First Affiliated Hospital
Author Profile
Shengsheng Zhou
Guangxi Medical University First Affiliated Hospital
Author Profile
Haiyan Yang
Guangxi Medical University First Affiliated Hospital
Author Profile
Fengxiang Huang
Guangxi Medical University First Affiliated Hospital
Author Profile
Qinli Mo
Guangxi Medical University First Affiliated Hospital
Author Profile
Yehong Bin
Guangxi Medical University First Affiliated Hospital
Author Profile
Dong Lan
Guangxi Medical University First Affiliated Hospital
Author Profile
Jie Ma
Guangxi Medical University First Affiliated Hospital
Author Profile
Zhigang Peng
Guangxi Medical University First Affiliated Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Castleman’s disease (CD) is a rare lymphoproliferative disease. In clinical practice, the first-line treatment of multicentric Castleman disease (MCD) includes glucocorticoid, conventional chemotherapy, immunomodulators, and anti-IL-6. However, not all patients benefited from the first-line regimen, a subset of patients does not respond to front-line therapy and is considered to have primary refractory MCD. Thus, it is urgent to explore alternative treatments to provide new hope for the treatment of MCD. We report two cases of refractory MCD who achieved complete remission by thalidomide combined with interleukin-2 and interferon α-2b. The literature on the treatment of refractory MCD is reviewed.